Journal of the American Academy of Dermatology
Volume 57, Issue 6 , Pages 1021-1025, December 2007

Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates

Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan

Background

Calcific uremic arteriolopathy (calciphylaxis) is a calcification syndrome that predominantly affects relatively small vessels and is a life-threatening entity usually seen in patients with end-stage renal disease. Intractable skin necrosis sometimes causes lethal sepsis because it progresses rapidly as a result of mechanical stress.

Objective

We sought to investigate the efficacy of etidronate disodium (bisphosphonates) in treating intractable ulcers occurred in a patient on hemodialysis accompanied with calcific uremic arteriolopathy.

Methods and Results

A 53-year-old patient receiving hemodialysis with chronic renal failure accompanied with calciphylaxis had bilateral leg ulcers caused by minor trauma. The aggressive debridement worsened his skin condition as is usually seen in pyoderma gangrenosum. It eventually healed by lowering calcium-phosphorus levels with the administration of bisphosphonates and with the continuous use of sevelamer hydrochloride.

Limitations

This study reporting a single case limits the interpretation of results.

Conclusion

Bisphosphonates may be effective in treating calciphylaxis and arteriosclerosis obliterans by reducing the formation of ectopic calcification around blood vessels.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by the Osaka Medical Research Foundation for Incurable Diseases, the Lydia O'Leary Memorial Foundation, a SHISEIDO Grant for Science Research, and a grant-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology.

 Conflicts of interest: None declared.

PII: S0190-9622(07)01047-X

doi:10.1016/j.jaad.2007.06.029

Journal of the American Academy of Dermatology
Volume 57, Issue 6 , Pages 1021-1025, December 2007